Granted Patent B2

US 12,590,975 · App. 17/935,294 · Granted Mar 31, 2026

Inventors: Joseph Anderberg (Encinitas, CA); Jeff Gray (Solana Beach, CA); Paul McPherson (Encinitas, CA); Kevin Nakamura (Encinitas, CA); James Patrick Kampf (San Diego, CA)

Assignee: bioMerieux, Inc.

G01N33/6893G01N33/6863G01N33/86G01N2333/4745G01N2333/522G01N2333/96447G01N2800/347G01N2800/50G01N2800/52

Abstract

Claims (21)

1 . A method of treating a subject comprising:

(a) detecting an elevated level of insulin-like growth factor-binding protein 7 (IGFBP7) in a urine sample obtained from the subject as compared to a predetermined threshold level, wherein the threshold level is selected based on results of a population study of individuals, and wherein the results separate the population into a first subpopulation of the individuals with a level of IGFBP7 that is greater than the threshold level and a second subpopulation of the individuals with a level of IGFBP7 that is less than the threshold level;

(b) determining that the subject has a current acute kidney injury based on the elevated level of insulin-like growth factor-binding protein 7 in the sample;

(c) treating the subject determined to have the current acute kidney injury, wherein the treatment comprises initiating renal replacement therapy, ceasing administration of compounds to the subject that are known to be damaging to the kidney, or modifying diuretic administration of compounds.

2 . The method of claim 1 , wherein the method further comprises contacting all or a portion of the urine sample with a binding reagent which specifically binds to insulin-like growth factor-binding protein 7, and

generating an assay result indicative of binding of insulin-like growth factor-binding protein 7 to the binding reagent.

3 . The method of claim 2 , wherein the assay result comprises a measured concentration of insulin-like growth factor-binding protein 7.

4 . The method of claim 2 , wherein the binding reagent is an antibody.

5 . The method of claim 1 , wherein the acute kidney injury is a RIFLE stage R acute kidney injury.

6 . The method of claim 1 , wherein the acute kidney injury is a RIFLE stage I acute kidney injury.

7 . The method of claim 1 , wherein the acute kidney injury is a RIFLE stage F acute kidney injury.

8 . The method of claim 1 , comprising initiating renal replacement therapy.

9 . The method of claim 1 , comprising ceasing administration of compounds to the subject that are damaging to the kidney.

10 . The method of claim 1 , comprising modifying diuretic administration of compounds used for treatment of a kidney disorder.

11 . The method of claim 1 , wherein the acute kidney injury is current prerenal acute renal failure (ARF).

12 . The method of claim 1 , wherein the acute kidney injury is intrinsic renal acute renal failure (ARF).

13 . The method of claim 1 , wherein the acute kidney injury is postrenal acute renal failure (ARF).

14 . The method of claim 1 , wherein the subject has been diagnosed with one or more of congestive heart failure, preeclampsia, eclampsia, diabetes mellitus, hypertension, coronary artery disease, proteinuria, renal insufficiency, glomerular filtration below the normal range, cirrhosis, serum creatinine above the normal range, and sepsis.

15 . The method of claim 1 , wherein the subject: (i) is undergoing or has undergone an acute medical event which predisposes the subject for developing the acute kidney injury; or (ii) has been exposed to an agent that predisposes the subject for developing the acute kidney injury.

16 . The method of claim 15 , wherein the acute medical event is major vascular surgery, coronary artery bypass, or other cardiac surgery.

17 . The method of claim 15 , wherein the agent is NSAIDs, cyclosporines, tacrolimus, aminoglycosides, foscarnet, ethylene glycol, hemoglobin, myoglobin, ifosfamide, heavy metals, methotrexate, radiopaque contrast agents, or streptozotocin.

Assignments (5)

Continuity (8)

References Cited (400)